Boston Scientific Corp Says Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success, Safety Of Acurate Neo Aortic Valve System
Boston Scientific Corp 
BSX:
LATE-BREAKING POST-MARKET STUDY DATA REINFORCE CLINICAL PROCEDURAL SUCCESS, SAFETY OF ACURATE NEO2™ AORTIC VALVE SYSTEM
IN EUROPEAN STUDY, PRIMARY SAFETY ENDPOINT OF ALL-CAUSE MORTALITY WAS 0.8% AT 30 DAYS